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Eighty-five patients with stable COPD (FEV1p80%) were examined by chest HRCT.
Emphysematous changes and bronchial wall thickening were evaluated visually, and
COPD patients were classified into three phenotypes: absence of emphysema, with
little emphysema with or without bronchial wall thickening (A phenotype),
emphysema without bronchial wall thickening (E phenotype), and emphysema with
bronchial wall thickening phenotype (M phenotype). Clinical characteristics were
compared among the three phenotypes.
The A phenotype group showed a higher prevalence of subjects who had never
smoked and patients with wheezing, higher values of body mass index (BMI) and
DLco, milder lung hyperinflation, and greater reversibility of airflow limitation
responsive to inhaled b2-agonist as compared with the other phenotypes. The degree
of emphysema was significantly associated with Brinkman index, lower BMI, decrease
in DLco, lower FEV1/FVC. The presence of bronchial wall thickening in A- and M-
phenotype was significantly associated with reversibility responsive to treatment
with inhaled corticosteroid and sputum eosinophilia.
These findings suggest that the morphological phenotypes of COPD show several
clinical characteristics and different responsiveness to treatment with bronchodi-
lators and inhaled corticosteroids.
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Chronic obstructive pulmonary disease (COPD) is a
disease state characterised by airflow limitation that
is not fully reversible, and that is usually progressive
and associated with an abnormal inflammatory
response of the lungs to noxious particles or gases
according to the GOLD guidelines.1 Pathological
changes characteristic of COPD are found in the
central and peripheral airways, lung parenchyma, and
pulmonary vasculature.2,3 The chronic airflow limita-
tion is attributed to narrowing of the small airway
lumen due to morphological changes and a decrease
in lung elastic recoil due to parenchyma destruction.
However, the relative contributions of these patholo-
gical changes of the large airway, small airway, and
emphysema toward irreversible airflow limitation and
clinical features vary between individuals, and the
pathophysiological pathways that lead to emphysema
and to small airway narrowing are independent of
each other.4,5 For example, morphologically, some
patients show severe emphysema accompanied with
or without bronchial wall thickening. On the other
hand, some patients do not show any apparent low
attenuation areas (LAA) in the lung fields on chest
high-resolution computed tomography (HRCT) but do
show severe irreversible airflow limitation.5–7 Clini-
cally, some patients show partial reversibility of
airflow limitation in response to inhaled bronchodila-
tors or inhaled corticosteroids (ICS), some patients
show production of greater amounts of sputum and
wheezing or sputum eosinophilia, and some complain
of severe dyspnoea or mild hypoxemia.8–10
We hypothesised that the diversity of morpholo-
gical changes may be associated with the differ-
ences in clinical features, including responsiveness
to bronchodilators or ICS. To clarify the hypothesis,
COPD was classified morphologically using HRCT
into the three morphological phenotypes in accor-
dance with the presence or absence of apparent
emphysema and bronchial wall thickening, and
examined the association with the morphological
characteristics on HRCT and clinical characteristics
including responsiveness to a bronchodilator or ICS
and sputum eosinophilia in each phenotype. If the
morphological phenotype will be associated with
the characteristics of clinical features, we will be
able to reconstruct the strategy for management of
COPD in accordance with the each phenotype.
Methods
Subjects
One hundred and twenty-four stable COPD pa-
tients, with FEV1/FVCo70% and FEV1 values lessthan 80% of the predicted value after inhalation of
a b2-agonist (moderate-to-severe COPD) were
recruited from outpatient clinics of three general
hospitals belonging to the investigation facilities
organised by the Ministry of Health, Labour and
Welfare in Japan from September 2002 to Septem-
ber 2004. COPD was diagnosed based on clinical
history and symptoms including constant exertional
dyspnoea, and pulmonary function characterised by
irreversible airflow limitation (FEV1/FVCo70%
after inhalation of a b2-agonist) in accordance with
the GOLD guidelines.1 Patients with late sequelae
of pulmonary tuberculosis, diffuse panbronchiolitis,
sinobronchitis, bronchiectasis or bronchiolitis ob-
literans due to autoimmune disease, severe cere-
bral-cardiovascular disease or events, or typical
bronchial asthma who showed repeated episodes of
paroxysmal dyspnoea characteristic of asthma and
patients having a history of asthma were excluded
from the study. We also left out of the analysis
those patients for which the diagnosis of asthma/
history of asthma could not be excluded. In
addition, patients who had taken ICS or oral
steroids, or had suffered from a respiratory tract
infection or exacerbation of airway disease in the
previous 6 weeks were also excluded. In the
present study, we included COPD patients who
had wheezing both at rest and on exertion or who
showed partial reversibility of airflow limitation in
response to b2-agonist inhalation or treatment with
ICS,10 but their airflow limitation did not reach
FEV1/FVCX70% and FEV1X80% of predicted value
after b2-agonist and ICS treatment. The study was
approved by the local research ethics committee,
and all patients gave their written informed
consent to participation. This study was supported
by the Ministry of Health, Labour and Welfare of
Japan.Protocol and measurements
During the first visit, the history of current illness,
including complications and histories of smoking
and exposure to noxious particles or gases other
than tobacco, were obtained, and physical exam-
ination, laboratory examinations, including serum
a1-antitrypsin, and chest X-ray, were performed.
During the second visit, pulmonary function tests,
including reversibility of airflow limitation by 20 mg
of inhaled procaterol hydrochloride, arterial blood
gas analysis, and analysis of inflammatory cells in
induced sputum, were examined. During the third
visit, chest HRCT scanning was performed, and
the patients were treated with 400 mg/day of
inhaled fluticasone propionate for 2–3 months.
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again obtained by spirometry.
HRCT protocol and evaluation of the degree
of emphysema and bronchial wall thickening
A helical CT scanner (Hi Speed Advantage; GE
Medical Systems, Milwaukee, WI) was used for
conventional contiguous scanning with a slice
thickness of 10mm to screen for chest abnormal-
ities, followed by HRCT scanning at full inspiration
(at TLC level) with 1-mm collimation of (120 kVp,
200mA, pitch 1.0). Four slices 1mm thick were
obtained at three anatomic levels at full inspira-
tion, i.e., near the superior margin of the aortic
arch (level of the upper lung field), at the level of
the carina (level of the middle lung field), and at
the level of the orifice of the inferior pulmonary
veins (level of the lower lung field). HRCT images
were photographed with a window setting appro-
priate for the lungs (window level from 700 to
900HU; width, from 800 to 1000HU). Emphysema
was scored visually as LAA in bilateral upper,
middle, and lower lung fields according to the
method of Goddard et al.11 The score in each
dimension was calculated according to the ratio of
LAA to occupy in the lung field as follows: score 0,
LAAo5%; score 1, 5%pLAAo25%; score 2,
25%pLAAo50%; score 3, 50%pLAAo75%; score 4,
75%XLAA. The severity of emphysema was graded
in accordance with the sum of scores at 6
dimensions as follows: grade 0, total score ¼ 0;
grade 1, total score ¼ 1–6; grade 2, total score ¼
7–12; grade 3, total score ¼ 13–18; grade 4, total
score ¼ 19–24. Bronchial wall thickening in all lung
fields was graded visually as reported previously12
as follows: grade 0, bronchial wall o30% adjacent
pulmonary artery diameter; grade 1, 30%pbron-
chial wallo50% adjacent pulmonary artery dia-
meter; grade 2, bronchial wallX50% adjacent
pulmonary artery diameter. HRCT images were
analyzed independently by two pulmonologists with
no knowledge of the patients’ clinical information.
Classification of COPD into three phenotypes
according to the findings of HRCT
The patients were classified into the three pheno-
types according to the visual HRCT findings as
follows: A phenotype is characterized by the
absence of emphysema or little emphysema show-
ing LAApgrade 1 regardless of having bronchial
wall thickening. E phenotype is characterized by
the presence of apparent emphysema of grade 2
and more than grade 2 (Xgrade 2) withoutbronchial wall thickening. M phenotype is charac-
terized by the combination with the presence of
apparent emphysema Xgrade 2 and bronchial wall
thickening Xgrade 1.Pulmonary function tests
Spirometry and measurement of DLco were per-
formed with a pulmonary function testing system
(Chestac-55V; Chest Co. Ltd., Tokyo, Japan). To
evaluate the reversibility of airflow limitation, FEV1
was measured before and 20min after inhalation of
b2-agonist (20 mg of procaterol hydrochloride) by
aerosol (metered-dose inhaler, MDI) with spacer.
Functional residual capacity (FRC) was measured
using a Body Box (Medgraphic, Ann Arbor, MI), after
which the subjects immediately inspired to total
lung capacity (TLC) and expired maximally to
residual volume (RV), thus allowing calculation of
lung volume and RV/TLC. Pulmonary function test
was performed by two special technicians accord-
ing to the ATS criterion. Two or three tests were
repeated to guarantee repeatability.Sputum collection and analysis
We collected sputum induced by the inhalation of
hypertonic saline as described previously.9 Briefly,
the method of sputum induction was as follows.
Prior to the induction of sputum, all subjects
inhaled a b2-agonist, and 3.5% hypertonic saline
nebulised with an ultrasonic nebuliser (NE-V10B,
Omron, Tokyo, Japan). If appropriate sputum could
not be obtained, 4.5% hypertonic saline was
nebulised for periods of 5min. The nebulisation
was continued for at least 10min and stopped after
15min or earlier if X2ml of a sputum sample of
good quality was obtained. The collected sputum
was then separated from contaminating saliva by
macroscopic examination, and the mucus plug was
removed from the dish to a sterile plastic container,
after which the volume of the sample was
determined. The sample was incubated with an
equal volume of Hank’s balanced salt solution
(HBSS) containing 1mM dithiothreitol (Sigma Che-
micals, Poole, UK) at 37 1C for 15min. After
removing the residual mucous, the eluent was used
to obtain total and differential cell counts. The
total cell count except that of squamous cells was
determined with a standard haemocytometer,
normalized for weight and expressed as
cells 105/g wet weight of sputum. Cell smears
were prepared with a centrifuge (Autosmear,
Sakura, Tokyo) and stained with May–Gru¨nwald–
Giemsa for differential cell counting. The slides
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differential leukocyte count.
Data analysis
The values shown in the text and tables are
means7SEM. The data distribution of the variables
in the various groups was first assessed with
Bartlett’s test. When the data for the variables
showed a normal distribution, they were compared
by one-way analysis of variance (ANOVA), followed
by multiple comparisons with the Tukey–Kramer
method. When the data for the variables did not
show a normal distribution, the variables were
compared with the Kruskal–Wallis test, followed by
multiple comparisons among groups with the non-
parametric Tukey–Kramer method. Simple ccorre-
lations between variables were examined by
calculating Pearson’s product correlation coeffi-
cient. Multiple, stepwise, logistic regression analy-
sis was performed to identify which variables were
significantly responsible for the presence of em-
physema Xgrade 2, or the presence of bronchial
wall thickening. Multiple, stepwise, linear regres-
sion analysis was also performed to identify which
variables were significantly associated with the
reversibility in response to a b2-agonist or the
treatment with ICS and the total score of LAA or the
grade of bronchial wall thickening independently.
The Po0:15 was used first to identify candidate
variables, and then removed variables from the
regression model if P-value was more than 0.1. All
statistical analyses were performed with the use of
a Windows-compatible software program (Stat Flex
ver. 5.0, Artech Ltd., Osaka, Japan). A P-value of
less than 0.05 was considered significant for the
results of all statistical analyses.Results
Population of COPD phenotypes
Of one hundred and twenty-four patients recruited
from our outpatient clinics, 7 patients complicated
with pulmonary fibrosis, 2 patients complicated
with late sequelae of pulmonary tuberculosis, 3
patients complicated with left-side heart failure, 2
patients complicated with lung cancer, and 3
patients complicated with sinobronchitis or bronch-
iectasis were excluded from this study. Seven
patients who showed a history of asthma and/or
repeated episodes of paroxysmal dyspnea charac-
teristic of asthma were also excluded from this
study. One patient whose FEV1/FVC increased over70% followed by the treatment with ICS was also
excluded. Fourteen patients were missing because
of failure to obtain appropriate sputum samples or
to obtain agreement about the treatment with ICS
or drop out during the treatment. Finally, eighty-
five patients with moderate-to-severe COPD were
examined in this study.
Eighty-five patients with COPD were classified
into three phenotypes according to HRCT findings.
Twenty-four patients with a mean LAA score of
0.170.1 were classified into the A phenotype group
(Fig. 1). Of the A phenotype group, 11 patients
(12.9% of the total) showed no bronchial wall
thickening, and 13 (15.3%) showed bronchial wall
thickening (grade 1, 10 patients; grade 2, 3
patients). Thirty patients were classified into the
E phenotype group. Thirty-one patients were
classified into the M phenotype group (bronchial
wall thickening grade 1, 28 patients; grade 2, 3
patients). There was no significant difference in
total LAA score between the E phenotype and M
phenotype groups (mean LAA score, 3.770.1 in E
phenotype and 3.570.1 in M phenotype). The
grade of bronchial wall thickening was significantly
greater in the M phenotype group (1.170.1 grade)
than that in the A phenotype group (0.770.1
grade).Clinical features of each phenotype
There were no significant differences in age, sex,
history of chronic sinusitis, age at starting smoking,
and the prevalence of exposure to noxious particles
or gases other than tobacco among the three
phenotypes (Table 1). Body mass index (BMI) was
significantly higher in the A phenotype group than
in the E or M phenotype groups, and only 12.5% of
patients in the A phenotype group showed
BMI o20 kg/m2, whereas 46.7% and 51.6% of
patents in the E phenotype and M phenotype
groups, respectively, showed a decrease in BMI.
The age at onset of exertional dyspnoea in
the A phenotype group was significantly higher
than that in the E phenotype group. The prevalence
of those who had never smoked was significantly
higher in the A phenotype group than in the other
phenotype groups. Brinkman index in the E pheno-
type group was significantly increased as compared
with those in the other phenotype groups. The
number of patients receiving long-term oxygen
therapy (LTOT) in the A phenotype group was
significantly lower than that in the E phenotype
group.
The prevalence of patients who complained of
coughing and sputum production showed no
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Figure 1 Constitution of the three phenotypes of COPD in the present study population classified according to the
dominancy of emphysema and bronchial wall thickening on chest HRCT findings. Absence of emphysema phenotype (A
phenotype): little emphysema (LAApgrade 1) with and without bronchial wall thickening. Emphysema without
bronchial wall thickening phenotype (E phenotype): emphysema Xgrade 2 without bronchial wall thickening.
Emphysema with bronchial wall thickening phenotype (M phenotype): combination of emphysema X grade 2 and
bronchial wall thickening.
Table 1 Characteristics of three phenotypes of COPD.
E phenotype M phenotype A phenotype
(n ¼ 30) (n ¼ 31) (n ¼ 24)
Age (yr) 70.771.0 73.171.0 69.971.8
Sex (F/M) 3/27 4/27 6/18
Body mass index (kg/m2) 20.370.5 19.870.6 23.270.6,yy
Age onset dyspnoea (yr) 61.871.4 64.271.4 65.772.2
History of sinusitis, n 7(23.3%) 5(16.1%) 6(25.0%)
Never smoker, n 0(0.0%) 0( 0.0%) 7(29.2%)
Bl (packs-yr) 66.174.7 51.875.3 38.976.9,yy
Age at starting smoking 21.070.5 21.270.8 20.570.7
History of noxious particles or gases
other than tobacco, n
12 (41.4%) 14(50.0%) 10(43.8%)
LTOT, n 8(26.7%) 6(22.6%) 1(4.2%)
Values are means7SEM. E phenotype, emphysema without bronchial wall thickening; M phenotype, emphysema with bronchial
wall thickening; A phenotype, absence of emphysema; Bl, Brinkman index; LTOT, long-term oxygen therapy.
Po0:05.
Po0:01 vs. E phenotype.
yyPo0:01 vs. M phenotype.
Y. Kitaguchi et al.1746significant differences among the three phenotypes
(Table 2). The A phenotype group included many
more patients who complained of wheezing both at
rest and on exertion as compared with the other
phenotype groups. Fletcher, Hugh-Jones dyspnoea
score was significantly lower in the A phenotype
group as compared with the other phenotype
groups.Pulmonary function tests and inflammatory
cell analysis of induced sputum
In the A phenotype group, lung hyperinflation
expressed by increased RV and TLC was significantly
milder and FEV1/FVC and DLco were signifi-
cantly higher as compared with those in the
other phenotype groups, although there was no
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Table 2 Symptoms in the three phenotypes of COPD.
E phenotype M phenotype A phenotype
(n ¼ 30) (n ¼ 31) (n ¼ 24)
Sputum
None 22.3% 16.1% 12.5%
A little 50.5% 54.8% 58.3%
Large amount 26.7% 29.0% 29.2%
Cough
None 50.0% 45.2% 45.8%
Productive cough 13.3% 12.9% 12.5%
Non-productive cough 36.7% 41.9% 41.7%
Wheezing
None 53.3% 32.3% 20.8%
On exertion 16.7% 19.3% 8.4%
Both exertion and rest 30.0% 48.4% 70.8%,y
Dyspnea (F-H-J classification) 3.070.2 3.270.2 2.370.2,yy
Values are means7SEM. E phenotype, emphysema without bronchial wall thickening; M phenotype, emphysema with bronchial
wall thickening; A phenotype, absence of emphysema; F-H-J, Flether, Hugh-Jones.
Po0.05 vs. E phenotype.
yPo0.05
yyPo0.01 vs. M phenotype.
Characteristics of COPD phenotypes 1747difference in FEV1 among the three phenotypes
(Table 3). Most of the patients in the A phenotype
group showed DLco values within the normal range.
Arterial blood gas analysis showed no significant
differences among the three phenotypes. On labora-
tory analysis, there were no cases of a1-antitrypsin
deficiency, and there were no significant differences
in serum CRP, a1-antitrypsin or peripheral eosinophil
counts among the three phenotypes.
The increases in FEV1 in response to a b2-agonist
were significantly higher in the A phenotype group
as compared with the other phenotype groups and
the increase in FEV1 in response to treatment with
400 mg/day of inhaled fluticasone propionate for
2–3 months were significantly higher in A and M
phenotype groups than in the E phenotype group
(Table 4). There were no significant differences in
the total cell counts in induced sputum. However,
eosinophil counts were significantly higher in the A-
and M-phenotype groups as compared with the E
phenotype group. When the patients were classi-
fied into two groups according to the reversibility
of airflow limitation, defined as an increase in FEV1
of 412% and 200ml from baseline values, in
response to inhaled b2-agonist or treatment with
ICS for 2–3 months,11 the prevalence of patients
showing reversibility was significantly higher in the
A phenotype group than in the E phenotype group
(Table 5). The patients who showed reversibility in
response to a b2-agonist also showed a significantlygreater increase in FEV1 after ICS treatment, and
there was a significant correlation between the
reversibility in response to b2-agonist and the
treatment with ICS (r ¼ 0:39, Po0:01). Further-
more, the reversibility in response to the treatment
with an ICS was also significantly correlated with
sputum eosinophilia (r ¼ 0:45, Po0:01). Multiple,
stepwise, linear regression analysis showed that
lower total LAA score (P ¼ 0:001) and sputum
eosinophil numbers (P ¼ 0:029) were significant
determinants for the reversibility in response to
b2-agonist, and the symptom of wheezing both at
rest and on exertion (P ¼ 0:047), sputum eosinophil
numbers (P ¼ 0:013), and the grade of bronchial
wall thickening (P ¼ 0:045) were significant deter-
minants for the reversibility in response to the
treatment with ICS.Characteristics of the patients with apparent
emphysema or bronchial wall thickening
among all COPD patients
When the patients in A phenotype were compared
with the other patients in E and M phenotype, who
showed apparent emphysema Xgrade 2 by the
multiple, stepwise, logistic regression analysis, A
phenotype was significantly characterized by lower
Brinkman index (P ¼ 0:028), no decreases in
BMI (P ¼ 0:009) and DLco (P ¼ 0:016), and milder
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Table 4 Responses to b2-agonist and inhaled corticosteroid, and cell analysis in induced sputum.
E phenotype M phenotype A phenotype
(n ¼ 30) (n ¼ 31) (n ¼ 24)
Response to b2 agonist
DFEV1 (ml) 94.0718.1 133.7721.6 253.3742.4
,y
%Change of FEV1 (%) 11.172.7 13.572.6 19.373.1

Response to treatment with inhaled corticosteroid
DFEV1 (ml) 116.2726.9 247.9743.6
 313.9774.4
% Change of FEV1 (%) 15.473.3 24.675.2 28.877.1
Sputum cell differentiation
Total cell ( 105/g) 104.1738.6 157.0742.4 82.3723.5
Macrophage (%) 10.471.8 10.070.8 12.273.7
Lymphocyte (%) 3.670.7 3.670.7 4.170.7
Neutrophil (%) 83.672.4 79.074.7 74.075.6
Eosinophil (%) 2.470.7 7.572.4 9.773.3
Values are means7SEM. E phenotype, emphysema without bronchial wall thickening; M phenotype, emphysema with bronchial
wall thickening; A phenotype, absence of emphysema.
Po0.05
Po0.05 vs. E phenotype.
yPo0.01 vs. M phenotype.
Table 3 Pulmonary function and laboratory data in three phenotypes of COPD.
E phenotype M phenotype A phenotype
(n ¼ 30) (n ¼ 31) (n ¼ 24)
VC (% of pred.) 97.373.4 90.472.7 86.174.1
FEV1 (%of pred.) 47.473.6 46.172.8 51.072.9
FEV1/FVC (%) 42.772.2 46.172.0 55.272.0
,yy
RV (% of pred.) 242.6714.3 209.9711.4 205.6711.7
RV/TLC (%) 56.371.9 56.272.3 56.972.0
FRC (% of pred.) 145.276.6 137.476.9 136.877.9
TLC (% of pred.) 139.774.4 123.373.1 120.773.8,yy
DLco (% of pred.) 51.373.5 60.673.6 84.974.3,yy
PaO2 (torr) 67.472.4 71.871.9 70.372.2
PaCO2 (torr) 41.070.9 41.770.9 42.071.1
CRP (mg/dl) 0.3670.10 0.2170.04 0.4770.17
a1-AT (mg/dl) 154.0710.0 148.074.7 137.0714.1
P. eosinophil (/mm3) 164.3759.0 299.7756.5 254.4747.5
Values are means7SEM. E phenotype, emphysema without bronchial wall thickening; M phenotype, emphysema with bronchial
wall thickening; A phenotype, absence of emphysema; CRP, C reactive protein; a1-AT, a1-antitrypsin; P. eosinophil, peripheral
eosinophil counts.
Po0.05.
Po0.05 vs. E phenotype.
yyPo0.01 vs. M phenotype.
Y. Kitaguchi et al.1748airflow limitation. When compared the patients in
A phenotype with and without bronchial wall
thickening, Fletcher, Hugh-Jones dyspnoea score
(1.870.3 vs. 2.770.2, Po0:05) and peripheral
eosinophil numbers (122725 vs. 353769/mm3,
Po0:05) were significantly higher in the patientswith bronchial wall thickening. However, there
were no significant differences in provocation of
noxious particles or gases, pulmonary function,
reversibility, and sputum findings
Multiple, stepwise, logistic regression analysis
revealed that the presence of emphysema Xgrade
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Table 5 Comparison of patients who showed partial reversibility [increase in FEV14200ml and 12%] in response
to b2-agonist or inhaled corticosteroid.
Reversibility [] Reversibility (+)
(A) Responsiveness to b2-agonist
E/M/A phenotype, n 27/26/13 3/5/11
Response to b2-agonist
DFEV1 (ml) 81.878.2 358.0731.3

% change of FEV1 (%) 8.571.0 31.973.9

Response to inhaled corticosteroid
DFEV1 (ml) 167.8727.0 358.8770.B

% change of FEV1 (%) 16.772.2 40.479.3

Sputum eosinophils (%) 4.271.1 12.273.9
(B) Responsiveness to inhaled corticosteroid
E/M/A phenotype, n 23/2/12 7/10/12
Response to b2-agonist
DFEV1 (ml) 102.1714.2 232.8732.7

% change of FEV1 (%) 9171.2 23.473.5

Response to inhaled corticosteroid
DFEV1 (ml) 67.9714.4 418.6740.7

% change of FEV1 (%) 8.471.5 41.274.8

Sputum eosinophils (%) 2.270.5 14.373.3
Values are means7SEM. E phenotype, emphysema without bronchial wall thickening; M phenotype, emphysema with bronchial
wall thickening; A phenotype, absence of emphysema.
po0.05.
po0.01 vs. Reversibility(—).
Characteristics of COPD phenotypes 17492 was significantly associated with Brinkman index
(P ¼ 0:028), lower BMI (P ¼ 0:009), decrease in
DLco (P ¼ 0:016), and lower FEV1/FVC (P ¼ 0:007),
and the presence of bronchial wall thickening was
significantly associated with Brinkman index
(P ¼ 0:032), Fletcher, Hugh-Jones dyspnoea score
(P ¼ 0:005), and reversibility in response to the
treatment with ICS (P ¼ 0:019) independently.
Multiple, stepwise, linear regression analysis also
showed a significant regression model for the total
score of LAA (r ¼ 0:79) comprised of Brinkman
index (P ¼ 0:046), without wheezing both at rest
and on exertion (P ¼ 0:036), lower BMI (P ¼ 0:003),
lower FEV1/FVC (Po0:001), and decrease in DLco
(Po0:001). This model accounted for 62.1% of total
score of LAA. The regression model for the grade of
bronchial wall thickening was significant (r ¼ 0:51)
and comprised of the following determinants;
Fletcher, Hugh-Jones dyspnoea score (P ¼ 0:013),
reversibility in response to the treatment with ICS
(P ¼ 0:099), and sputum eosinophilia (P ¼ 0:002).
However, there was a significant correlation be-
tween reversibility in response to the treatment
with an inhaled corticosteroid and sputum eosino-
philia (r ¼ 0:45, Po0:01). If sputum eosinophilia
was removed, the regression model was also
significant (r ¼ 0:44, Po0:01) and reversibility inresponse to the treatment with ICS became more
significant (P ¼ 0:004).Discussion
In the present study, 85 stable moderate-to-severe
COPD patients were classified into groups showing
absence or less of emphysema phenotype (A pheno-
type), emphysema without bronchial wall thicken-
ing phenotype (E phenotype) and emphysema with
bronchial wall thickening phenotype (M phenotype)
in accordance with the findings of HRCT. In the A
phenotype group, the prevalence of those who had
never smoked and patients with wheezing not only
on exertion but also at rest, and the reversibility of
airflow limitation in response to inhaled b2 agonist
were significantly greater as compared with those
in the other phenotype groups. Patients with the A
phenotype also showed significantly greater rever-
sibility of airflow limitation in response to treat-
ment with ICS, and a significant increase in sputum
eosinophil counts as compared with those in the E
phenotype group. In the M phenotype group, the
reversibility of airflow limitation in response to ICS
was also significantly greater and the eosinophil
ARTICLE IN PRESS
Y. Kitaguchi et al.1750counts in sputum were higher than those in the E
phenotype group. Multiple, stepwise, linear regres-
sion analysis revealed that Brinkman index, lower
BMI, decrease in DLco, lower FEV1/FVC, and no
symptom of wheezes both at rest and on exertion
were significant determinants for the total score of
LAA. When all patients were classified into the two
groups according to the presence or absence of
bronchial wall thickening, dyspnoea score, reversi-
bility in response to the treatment with ICS, and
sputum eosinophilia were significant determinants
for the presence of bronchial wall thickening.
These findings suggested that the morphological
phenotypes of COPD classified according to dom-
inancy of emphysema and the presence of bronchial
wall thickening show several clinical characteristics
and different responses to the treatment with
bronchodilators and ICS.
COPD is a disease state characterized by airflow
limitation that is not fully reversible. However, the
degree of reversibility of the airflow limitation in
response to bronchodilators or treatment with ICS
varies among individuals.9,13,14 We have shown
that, in patients with COPD, airway eosinophilia is
related to reversibility of airflow limitation after a
short course of oral steroids.9 It has also been
demonstrated that COPD patients with partial
reversibility of airflow limitation in response to a
b2-agonist show sputum eosinophilia as compared
with healthy controls.10 In the present study, the
patients who showed reversibility in response to a
b2-agonist or treatment with ICS showed higher
eosinophil counts in induced sputum as compared
with those who showed no reversibility, and there
was a significant correlation between the reversi-
bility in response to ICS and sputum eosinophilia.
Complete reversibility of airflow limitation is
typical of asthma, but partially reversible airflow
limitation may be present in patients with COPD
who have no evidence of asthma or atopy.15 Indeed,
significant reversibility of airflow limitation after
use of bronchodilators and/or corticosteroids may
be present in up to 30% of stable patients with
COPD.16 However, there have been no previous
reports about the characteristics on chest HRCT
imaging of patients with COPD showing partial
reversibility of airflow limitation. The present study
indicated that the prevalence of patients showing
partial reversibility of airflow limitation in response
to a b2-agonist or treatment with ICS was higher in
A phenotype or M phenotype as compared with E
phenotype. Multiple, stepwise, linear regression
analysis also showed that the reversibility in
response to a bronchodilator was significantly
associated with lower emphysema score and in-
creased eosinophils in sputum, and the presence ofbronchial wall thickening was significantly asso-
ciated with the reversibility in response to the
treatment with ICS being correlated with sputum
eosinophilia, and twenty-three of 46 patients who
showed bronchial wall thickening demonstrated
reversibility in response to b2-agonist or ICS
therapy. Therefore, bronchial wall thickening
and/or sputum eosinophilia may be one indicator
for predicting the better responsive to the treat-
ment with ICS. Although increased airway wall
thickening in the small airways, but not in the large
airway, mainly contributes to airflow limitation in
COPD,17 it has been demonstrated that the wall
thickening in large or intermediate airways reflects
the wall thickening in smaller airways.18 Therefore,
patients who show bronchial wall thickening in
large or intermediate airways on HRCT may also
have increased airway inflammation and wall
thickening in the small airway. The airway inflam-
mation at small airways may be implicated in the
reversibility by bronchodilators or ISC. On the
contrary, in the E phenotype, the airway wall
thickening in the small airway may be mild, and the
airflow limitation is thought to be mainly due to the
decreased elastic recoil. Therefore, it may be
reasonable that patients in the E phenotype group
hardly show reversibility in response to treatment
with a bronchodilator or ICS. Reversibility in
response to bronchodilators or the treatment with
ICS and sputum eosinophilia are one of the typical
characteristics of asthma, and bronchial wall
thickening has been commonly observed in asthma
developed airway remodelling secondary to long-
standing asthma over time.19 However, it can not
be concluded that these COPD patients were
complicated with asthma, but these COPD patients
may have an asthmatic component. It may become
difficult to distinguish COPD from asthma showing
irreversible airflow limitation due to airway remo-
delling in phenotype A, especially in never smo-
kers.20 Four subjects of seven never smokers in A
phenotype showed sputum eosinophilia and partial
reversibility in response to a b2-agonist and ICS
(DFEV1: 320, 360, 390, 1190ml). Three of these
subjects showed bronchial wall thickening. We
cannot exclude the possibility that these patients
may be asthma with fixed airflow limitation due to
airway remodelling. However, these patients com-
plained of coughing and dyspnoea on exertion, but
did not have asthma history and show typical
asthma symptoms, such as repeated episodes of
paroxysmal dyspnoea. It is also possible that these
patients with sputum eosinophilia can be diagnosed
as having eosinophilic bronchitis, because some
eosinophilic bronchitis patients develop irreversi-
ble airflow limitation.21 These findings may suggest
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due to airway remodelling and without typical
asthma symptoms or eosinophilic bronchitis may be
diagnosed as phenotype A in COPD. However, even
if the four never smokers in A phenotype were
excluded from the analysis, the reversibility in
response to b2-agonist and ICS treatment was still
significantly greater than that in E phenotype.
Epidemiological studies have shown that 5–12% of
patients with a diagnosis of COPD have never
smoked,22 and these subjects are predominantly
female and can be divided into at least two
pathological subgroups, one of which may be
associated with organ-specific autoimmune dis-
ease, while the other shows sputum eosinophilia.23
In the present study, none of the patients had
organ-specific autoimmune disease. Three of 7
never smokers in A phenotype had no sputum
eosinophilia and did have sputum neutrophilia. Two
of these patients had been exposed to passive
smoking for a long time at home. Four patients had
a history of long-standing provocation of noxious
particles or gases other than tobacco, such as
organic solvents, mushroom spores, and carbon
dust from boiler. When compared the patients with
and without bronchial wall thickening, there were
no significant differences in provocation of noxious
particles or gases, pulmonary function, reversibil-
ity, and sputum findings because of small numbers.
It may be interesting the difference between the
patients with and without bronchial wall thickening
in phenotype A, further study will be needed.
It is important to determine the differences
between patients who will benefit from bronchodi-
lators or inhaled corticosteroid treatment and
those who will not. Sputum inflammation para-
meters and morphological phenotypes accessed by
HRCT may help in identifying those patients who
will respond to selective therapy.Acknowledgments
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